ORGO vs SOLV: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ORGO and SOLV share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ORGO and SOLV exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures, and commercializes products for the advanced wound care and surgical and sports medicine markets. Its advanced wound care line includes bioengineered and tissue-based products such as Apligraf, a bi-layered skin substitute for venous leg ulcers and diabetic foot ulcers; PuraPly and PuraPly AM, an antimicrobial wound matrix; and Affinity, a fresh human placental allograft. Its surgical and sports medicine products include ReNu, a cryopreserved amniotic suspension allograft, and NuCel. The company became publicly traded in 2018 through a SPAC merger with Avista Healthcare Public Acquisition Corp. and trades on the Nasdaq under the ticker ORGO. Because a large portion of its wound care revenue is billed to Medicare, the business is unusually sensitive to how the Centers for Medicare and Medicaid Services chooses to pay for skin substitutes.

Full ORGO guide

Solventum is a healthcare company that was spun off from 3M in 2024, combining 3M's former Health Care business into a standalone public company. It operates across several healthcare segments: medical surgical products (wound care, advanced dressings, surgical supplies, infection prevention), dental and orthodontic solutions, health information systems (clinical documentation, coding, and revenue-cycle software for hospitals), and purification and filtration (including water and biopharma filtration). The company makes money selling consumable medical products to hospitals and clinics, software and services to health systems, and filtration technology to industrial and life-science customers. As a recent spin-off, Solventum's story centers on standing up independent operations, paying down debt inherited at separation, stabilizing growth, and improving margins. It holds established brands and large installed bases in several niches. Headquartered in Maplewood, Minnesota, it serves customers across hospital, dental, and industrial end markets globally.

Full SOLV guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ORGO drivers: CMS reimbursement reset and market adaptation; ReNu BLA in knee osteoarthritis.
• SOLV drivers: Recurring consumable and software revenue; Spin-off self-help and margin expansion.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is Medicare reimbursement policy: a large share of revenue depends on how CMS pays for skin substitutes, and the CY 2026 payment reform already drove a sharp advanced wound care revenue decline and a large cut to full-year guidance versus 2025. For SOLV, as a recent spin-off, Solventum carries meaningful debt taken on at separation and must prove it can grow organically after years inside 3M, where the business reportedly underinvested.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ORGO if you believe its drivers more; SOLV if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ORGO and SOLV guides.

ORGO. Figures here are qualitative and tied to the asOf date; verify live numbers in the latest filings before acting. Because 2026 is a reimbursement-driven transition year with sharply lower guidance, trailing and forward earnings multiples are unreliable, and the stock's value hinges more on whether the wound care market normalizes and whether ReNu is approved than on any single quarter's results. Do not treat any of this as a price target or a recommendation.

SOLV. Solventum trades at a discount to faster-growing medtech peers, reflecting its slow top-line growth, elevated post-spin debt, and the work still required to prove independent execution. The qualitative profile is a turnaround and self-help story: stabilize growth, reduce leverage, and expand margins. Successful deleveraging and portfolio reshaping are the key swing factors.

Headline figures (approximate, Jul 2026): ORGO shows revenue trajectory Guided full-year 2026 net revenue sharply below record 2025, reflecting a projected double-digit percentage decline driven by CMS reimbursement and coverage changes, advanced wound care Reported a steep year-over-year decline in early 2026, the segment most exposed to the skin-substitute payment reform, profitability Under pressure during the 2026 transition as revenue contracts faster than the cost base; management frames 2026 as a reset year with recovery targeted for 2027, market cap Small-cap; the stock traded at only a few dollars per share in mid-2026, so market value is modest relative to its former highs; SOLV shows revenue (ttm) ~$8 billion, revenue growth low-single-digit, roughly flat to slightly up, operating margin ~20% on an adjusted basis, net debt elevated, inherited at the 3M separation.

ORGO and SOLV are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ORGO and SOLV exposure against your real portfolio. It is not an investment adviser.